SHR-1905 Injection

DRUG5 trials

Sponsors

Guangdong Hengrui Pharmaceutical Co., Ltd

Conditions

Adolescent AsthmaAsthmaChronic Rhinosinusitis With Nasal PolypsModerate-to-severe Atopic Dermatitis

Phase 2

Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps

CompletedNCT05891483

Guangdong Hengrui Pharmaceutical Co., LtdChronic Rhinosinusitis With Nasal Polyps

Start: 2023-09-04End: 2026-01-21Updated: 2026-07-22

Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy of Subcutaneous Injection of SHR-1905 in Adolescent Asthmatic Subjects - an Open-label, Single-dose Phase II Clinical Study

CompletedNCT06786455

Guangdong Hengrui Pharmaceutical Co., LtdAdolescent Asthma

Start: 2025-01-23End: 2025-12-03Updated: 2025-12-18

A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis

RecruitingNCT07211542

Guangdong Hengrui Pharmaceutical Co., LtdModerate-to-severe Atopic Dermatitis

Start: 2025-11-07End: 2027-02-01Target: 75Updated: 2026-04-08

Phase 3

A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma

RecruitingNCT07098403

Guangdong Hengrui Pharmaceutical Co., LtdAsthma

Start: 2025-09-03End: 2028-06-30Target: 408Updated: 2025-09-09

Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps

RecruitingNCT07132827

Guangdong Hengrui Pharmaceutical Co., LtdChronic Rhinosinusitis With Nasal Polyps

Start: 2025-08-28End: 2028-04-30Target: 280Updated: 2025-11-17